Ergoteles LLC lessened its holdings in Neuronetics, Inc. (NASDAQ:STIM – Get Rating) by 10.6% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 111,805 shares of the company’s stock after selling 13,295 shares during the period. Ergoteles LLC owned approximately 0.41% of Neuronetics worth $356,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. raised its holdings in shares of Neuronetics by 16.6% in the 3rd quarter. Envestnet Asset Management Inc. now owns 124,032 shares of the company’s stock valued at $394,000 after purchasing an additional 17,628 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Neuronetics by 247.3% during the third quarter. Dimensional Fund Advisors LP now owns 100,781 shares of the company’s stock worth $319,000 after buying an additional 71,765 shares in the last quarter. Spouting Rock Asset Management LLC boosted its holdings in Neuronetics by 100.7% during the third quarter. Spouting Rock Asset Management LLC now owns 20,962 shares of the company’s stock worth $67,000 after buying an additional 10,517 shares in the last quarter. Prudential Financial Inc. purchased a new stake in Neuronetics during the third quarter worth about $45,000. Finally, Millrace Asset Group Inc. raised its position in Neuronetics by 2.5% during the third quarter. Millrace Asset Group Inc. now owns 645,401 shares of the company’s stock worth $2,052,000 after acquiring an additional 15,670 shares during the last quarter. Hedge funds and other institutional investors own 62.90% of the company’s stock.
Insider Activity
In other news, CEO Keith J. Sullivan sold 25,154 shares of the company’s stock in a transaction on Monday, February 13th. The shares were sold at an average price of $5.49, for a total value of $138,095.46. Following the completion of the transaction, the chief executive officer now directly owns 1,210,845 shares in the company, valued at $6,647,539.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, major shareholder Cannell Capital Llc sold 4,896 shares of the stock in a transaction dated Friday, January 13th. The shares were sold at an average price of $6.30, for a total value of $30,844.80. Following the sale, the insider now owns 2,942,241 shares of the company’s stock, valued at approximately $18,536,118.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Keith J. Sullivan sold 25,154 shares of the stock in a transaction dated Monday, February 13th. The shares were sold at an average price of $5.49, for a total transaction of $138,095.46. Following the completion of the transaction, the chief executive officer now owns 1,210,845 shares of the company’s stock, valued at approximately $6,647,539.05. The disclosure for this sale can be found here. Over the last three months, insiders sold 321,565 shares of company stock worth $2,030,196. 5.20% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Neuronetics Stock Performance
Shares of STIM stock opened at $5.27 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.68 and a current ratio of 4.02. Neuronetics, Inc. has a one year low of $1.98 and a one year high of $6.95. The company has a 50 day moving average price of $5.99 and a 200 day moving average price of $4.80. The firm has a market capitalization of $143.45 million, a price-to-earnings ratio of -3.85 and a beta of 2.03.
Neuronetics Company Profile
Neuronetics, Inc commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients.
Featured Articles
- Get a free copy of the StockNews.com research report on Neuronetics (STIM)
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
- Taiwan Semiconductor Manufacturing Expanding in the West
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.
